Get the latest news and blog posts from APCI, including press releases and articles about advocacy actions, industry happenings, clinical pharmacy information, independent pharmacy operations, and much more.
APCI urges federal regulators to crack down on PBM-insurer consolidation, calling for stronger merger scrutiny to protect competition, patient access, and fair drug pricing.
BESSEMER, Ala. (May 24, 2023) – In a letter sent to one of the largest investors in America’s Big Three pharmacy benefit manager companies (PBMs), American Pharmacy Cooperative, Inc. (APCI)… Read More »
APCI endorses bipartisan legislation to end PBM spread pricing in Medicaid, calling it a critical step toward transparency, fair reimbursement, and lower costs for patients and taxpayers.
APCI’s “Choice Member Campaign” earns a prestigious MarCom Gold Award, recognizing a high-impact digital effort promoting top-performing independent pharmacies.
BESSEMER, Ala. (Sept. 20) – A judge’s decision to allow the merger between UnitedHealth Group and Change Healthcare to move forward is likely to prove detrimental to patients, providers, and… Read More »
APCI warns that while Congress’s drug pricing proposals make progress, they fall short by failing to address the root problem: anti-competitive PBM practices driving costs and limiting patient access.
APCI urges federal regulators to block Prime Therapeutics’ acquisition of Magellan Rx, warning it would reduce competition and worsen prescription drug pricing and access.
APCI applauds the FTC’s unanimous decision to launch a sweeping investigation into PBM practices, marking a major step toward transparency and accountability in drug pricing.
APCI urges the FTC to investigate PBM practices, citing widespread anti-competitive behavior that drives up drug costs and limits patient access.
APCI challenges claims that Medicaid payment parity would cost $1 billion in New York, arguing the true figure is far lower and urging transparency around the state’s analysis.